Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis

Blood Pressure

Volumn 19, Issue 3, 2010, Pages 164-168

  Viigimaa, Margus ^a   Abina, Jelena ^a   Zemtsovskaya, Galina ^a   Tikhaze, Alla ^b   Konovalova, Galina ^b   Kumskova, Elena ^b   Lankin, Vadim ^b  

^a TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Biomarkers; Malondialdehyde modified low density lipoproteins

Indexed keywords

BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONDIALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ESTONIA; GLUTATHIONE OXIDATION; HEART MUSCLE FIBROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 77952871796     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.484158     Document Type: Article

References (16)

1. Lankin V. The enzymatic systems in the regulation of free radical lipid peroxidation. In: Free radicals, nitric oxide, and inflammation: Molecular, biochemical, and clinical aspects. Amsterdam: IOS Press; 2003, NATO Science Series vol. 344. p 8 - 23.
2. Lankin V, Tikhaze A. Free radical lipoperoxidation during atherosclerosis and antioxidative therapy of this disease. In: Free radicals, nitric oxide, and inflammation: Molecular, biochemical, and clinical aspects. Amsterdam: IOS Press; 2003, NATO Science Series vol. 344. p. 218 - 231.
3. Lankin VZ, Tikhaze AK, Kukharchuk VV, Konovalova GG, Pisarenko OI, Kaminnyi AI, et al. Antioxidants decrease the intensification of low density lipoprotein free radical peroxidation during therapy with statins. Mol Cell Biochem. 2003; 249 Suppl 1/2:129-140.
4. Lankin VZ, Tikhaze AK, Kapel'ko VI, Shepel'kova GS, Shumaev KB, Panasenko OM, et al. Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress. Biochemistry. 2007;72 Suppl 10:1081-1090.
5. Lankin VZ, Lisina MO, Arzamastseva NE, Konovalova GG, Nedosugova LV, Kaminnyi AI, et al. Oxidative stress in atherosclerosis and diabetes. Bull Exp Biol Med. 2005;140 Suppl 1:41-43.
6. Nedosugova LV, Lankin VZ, Balabolkin MI, Konovalova GG, Lisina MO, Antonova KV, et al. Interrelation between compensation of carbohydrate metabolism and severity of manifestations of oxidative stress in type II diabetes mellitus. Bull Exp Biol Med. 2003;136 Suppl 2:132-134.
7. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol. 2006;97 Suppl 5:640-645.
8. Girona J, Manzaranes JM, Marimon F, Cabre A, Heras M, Guardiola M, et al. Oxidized to non-oxidized lipoprotein ratios are associated with atherosclerosis and the metabolic syndrome in diabetic patients. Nutr Metab Cardiovasc Dis. 2007;18 Suppl 5:380-387.
9. Imazu M, Ono K, Tadehara F, Kajiwara K, Yamamoto H, Sumii K, et al. Plasma levels of oxidized low density lipoprotein are associated with stable angina pectoris and modalities of acute coronary syndrome. Int Heart J. 2008;49 Suppl 5:515-524.
10. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis Circulation. 2008;118 Suppl 1:75-83.
11. Rietzschei ER, Langlois M, De Buyzere ML, Segers P, De Bacquer D, Bekaert S, et al. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension. 2008;52 Suppl 3:535-541.
12. Protocol and Guidelines. Countrywide Integrated Noncommunicable Diseases Intervention (CINDI) Programme. Copenhagen: WHO Regional Office for Europe; 1996.
13. Irodova NL, Lankin VZ, Konovalova GG, Kochetov AG, Chazova IE. Oxidative stress in patients with primary pulmonary hypertension. Bull Exp Biol Med. 2002;133 Suppl 6:580-582.
14. Arzamastseva NE, Lankin VZ, Konovalova GG, Tikhaze AK, Ageev FT, Lapina YV, et al. Oxidative stress in patients with chronic heart failure and type II diabetes mellitus. Bull Exp Biol Med. 2007;143 Suppl 2:207-209.
15. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year old men (AIR Study). J Internal Med. 2002;252 Suppl 2:440-447.
16. Verhoye E, Langlois MR. Circulating oxidized low-density lipoprotein: A biomarker of atherosclerosis and cardiovascular risk. Clin Chem Lab Med. 2009;47 Suppl 2:128-137.